Compile Data Set for Download or QSAR
Report error Found 58 Enz. Inhib. hit(s) with Target = 'MLL1-WRAD2 complex'
TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552984BDBM552984(4-(difluoromethyl)-N-[4- fluoro-5-(2-morpholin-4- ...)
Affinity DataIC50: 36nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552953BDBM552953(US11319299, Example 8 | US11319299, Example Table...)
Affinity DataIC50: 43nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552953BDBM552953(US11319299, Example 8 | US11319299, Example Table...)
Affinity DataIC50: 43nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552952BDBM552952(N-[2-[(3S)-3,4- dimethylpiperazin-1-yl]- 4-fluoro-...)
Affinity DataIC50: 54nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552981BDBM552981(N-[5-(2-cyanopyrimidin- 5-yl)-4-fluoro-2-[(3S,5R)-...)
Affinity DataIC50: 75nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552987BDBM552987(N-[2-[(3R)-3- (dimethylamino)pyrrolidin- 1-yl]-4-f...)
Affinity DataIC50: 106nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552982BDBM552982(N-[4-fluoro-5-(6- morpholin-4-ylpyridin-3- yl)-2-[...)
Affinity DataIC50: 111nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552989BDBM552989(N-[5-[6- (cyclopropylmethoxy) pyridin-3-yl]-4-fluo...)
Affinity DataIC50: 174nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552978BDBM552978(N-[4-fluoro-5-(4- morpholin-4-ylphenyl)-2- [(3R,5S...)
Affinity DataIC50: 182nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552966BDBM552966(4-(difluoromethyl)-N-[4- fluoro-2-(4-methylpiperaz...)
Affinity DataIC50: 213nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552948BDBM552948(US11319299, Example 3 | N-[4-fluoro-2-(4- methylpi...)
Affinity DataIC50: 272nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552967BDBM552967(N-[2-[3-(dimethylamino) pyrrolidin-1-yl]-4-fluoro-...)
Affinity DataIC50: 272nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552986BDBM552986(N-[4-fluoro-5-pyridin-4- yl-2-[(3R,5S)-3,4,5- trim...)
Affinity DataIC50: 316nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552948BDBM552948(US11319299, Example 3 | N-[4-fluoro-2-(4- methylpi...)
Affinity DataIC50: 380nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552962BDBM552962(N-[5-(2-cyanopyrimidin- 5-yl)-4-fluoro-2-(4- methy...)
Affinity DataIC50: 467nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 553001BDBM553001((S)-N-(4-(3,4- dimethylpiperazin-1-yl)-6- fluoro-3...)
Affinity DataIC50: 478nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552985BDBM552985(N-[4-fluoro-5-pyridin-3- yl-2-[(3R,5S)-3,4,5- trim...)
Affinity DataIC50: 620nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552990BDBM552990(N-[5-[2- (dimethylamino)pyrimidin- 5-yl]-4-fluoro-...)
Affinity DataIC50: 774nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552995BDBM552995(N-(4-(3,4-dimethylpiperazin- 1-yl)-6-fluoro-3'- (m...)
Affinity DataIC50: 780nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552949BDBM552949(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- (6-morp...)
Affinity DataIC50: 820nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 553006BDBM553006(US11319299, Comp. No. 56 | US11319299, Example 56 ...)
Affinity DataIC50: 864nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552951BDBM552951(N-[2-[(3R)-3,4- dimethylpiperazin-1-yl]- 4-fluoro-...)
Affinity DataIC50: 885nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552954BDBM552954(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- (2-pyrr...)
Affinity DataIC50: 984nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552956BDBM552956(N-[5-[2-(cyclohexylamino) pyrimidin-5-yl]-4-fluoro...)
Affinity DataIC50: 993nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552980BDBM552980(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- [6-(oxa...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552983BDBM552983(N-[4-fluoro-5-(2- methylpyrimidin-5-yl)-2- [(3S,5R...)
Affinity DataIC50: 1.01E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 553002BDBM553002(N-(6-fluoro-3'- (morpholinomethyl)-4- ((3R,5S)-3,4...)
Affinity DataIC50: 1.28E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552950BDBM552950(N-[5-(1,3-benzodioxol-5- yl)-4-fluoro-2-(4- methyl...)
Affinity DataIC50: 1.31E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 553003BDBM553003(N-(4-(3-(dimethylamino) pyrrolidin-1-yl)-6-fluoro-...)
Affinity DataIC50: 1.49E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552959BDBM552959(N-[5-[6-(cyclohexylamino) pyridin-3-yl]-4-fluoro-2...)
Affinity DataIC50: 1.49E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 553008BDBM553008(US11319299, Example 58 | N-(5-(2- morpholinopyrimi...)
Affinity DataIC50: 1.57E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552994BDBM552994(N-(3'-((cyclopentylamino) methyl)-6-fluoro-4-(4- m...)
Affinity DataIC50: 1.64E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552963BDBM552963(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- [2-(2,2...)
Affinity DataIC50: 2.07E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552957BDBM552957(N-[5-(2-ethoxypyrimidin- 5-yl)-4-fluoro-2-(4- meth...)
Affinity DataIC50: 2.07E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552996BDBM552996(US11319299, Example 60 | N-(4-fluoro-2-(4- methylp...)
Affinity DataIC50: 2.29E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552933BDBM552933(US11319299, Example 2 | N-[4-fluoro-2-(4- methylpi...)
Affinity DataIC50: 2.71E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552933BDBM552933(US11319299, Example 2 | N-[4-fluoro-2-(4- methylpi...)
Affinity DataIC50: 2.71E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552977BDBM552977(4-fluoro-N-[4-fluoro-5- (2-morpholin-4- ylpyrimidi...)
Affinity DataIC50: 2.74E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552971BDBM552971(4-fluoro-N-[4-fluoro-5- (2-morpholin-4- ylpyrimidi...)
Affinity DataIC50: 3.34E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552965BDBM552965(N-[5-(2,4- dimethoxypyrimidin-5- yl)-4-fluoro-2-(4...)
Affinity DataIC50: 3.67E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552991BDBM552991(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- [6-(mor...)
Affinity DataIC50: 4.91E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552968BDBM552968(N-[5-(3,6-dihydro-2H- pyran-4-yl)-4-fluoro-2- (4-m...)
Affinity DataIC50: 6.65E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552955BDBM552955(N-[5-[2-(cyclopropylamino) pyrimidin-5-yl]-4-fluor...)
Affinity DataIC50: 8.36E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 553000BDBM553000((R)-N-(4-(3,4- dimethylpiperazin-1-yl)-6- fluoro-3...)
Affinity DataIC50: 9.41E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 50164794BDBM50164794(CHEMBL3798846 | US11174250, Example Table4.1.1 | U...)
Affinity DataIC50: 9.50E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552958BDBM552958(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- (2-meth...)
Affinity DataIC50: 9.53E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552964BDBM552964(N-[4-fluoro-2-(4- methylpiperazin-1-yl)-5- pyrimid...)
Affinity DataIC50: 9.83E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552988BDBM552988(N-[2-[(3S)-3- (dimethylamino)pyrrolidin- 1-yl]-4-f...)
Affinity DataIC50: 9.85E+3nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552998BDBM552998(N-(4-fluoro-2-(4- methylpiperazin-1-yl)-5- (5-(((t...)
Affinity DataIC50: 1.12E+4nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

TargetMLL1-WRAD2 complex(Human)
Propellon Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 552932BDBM552932(4-fluoro-N-[4-fluoro-2- (4-methylpiperazin-1-yl)- ...)
Affinity DataIC50: 1.50E+4nMAssay Description:Compound potency was assessed through incorporation of 3H-SAM into oligonucleosomes purified from HeLa cells. Specifically, recombinant human MLL1 (a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
US Patent

Displayed 1 to 50 (of 58 total ) | Next | Last >>
Jump to: